about
Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT.T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production.Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination.Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.Just one position-independent lysine residue can direct MelanA into proteasomal degradation following N-terminal fusion of ubiquitin.Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT CellsAn Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy.Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype.A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells.O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients.Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.Autocrine TNF is critical for the survival of human dendritic cells by regulating BAK, BCL-2, and FLIPL.Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA.Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes.A fast and robust method to clone and functionally validate T-cell receptors.HIV-1 mRNA electroporation of PBMC: a simple and efficient method to monitor T-cell responses against autologous HIV-1 in HIV-1-infected patients.BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma.Effective clinical-scale production of dendritic cell vaccines by monocyte elutriation directly in medium, subsequent culture in bags and final antigen loading using peptides or RNA transfection.Triggering of NF-κB in cytokine-matured human DCs generates superior DCs for T-cell priming in cancer immunotherapy.Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.T Cell Telomere Length in HIV-1 Infection: No Evidence for Increased CD4+ T Cell TurnoverMild hyperthermia enhances human monocyte-derived dendritic cell functions and offers potential for applications in vaccination strategies.In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8(+) T-cell epitope
P50
Q33188519-21E3C900-2B22-43D9-85F5-CBECC811361FQ33235057-0C93DD3D-9B06-4AE9-9B66-41B8A3B4C578Q33887689-7BFDD148-C6AC-4332-9988-2E062D0A111FQ34166288-9CE447F6-AC62-4F82-962E-D7F153E0A5DDQ34438014-A8B6C1DD-9A19-433C-9B07-7E71904FF20DQ34581001-F933719F-EE64-4B23-AFB6-D94C650EFE1AQ35308252-6762FE60-9EEA-4C44-AF83-FA70792781CEQ35677421-118524B0-0F01-43E7-AE09-717B31ADDC61Q37145706-2642BFBF-DC9F-43AB-98A6-8E747F1C8226Q38072377-2461275B-E830-4AFF-8210-E62CD5914F76Q38756454-6F0D86D6-1560-4C4E-B02C-D2EAA4352D99Q38823747-E26831DA-143E-440A-90C8-9A94420AF90EQ38852674-D47AD01B-9128-4209-8A41-32C7E1A99E58Q38897933-32F4D1C9-C3CE-44E4-A8B3-194720AD5A6BQ38983814-B12054EF-E590-4323-9F89-199F5DB29C53Q39025449-2B55E778-C63A-4520-ABB1-666068E1CA4FQ39887434-F92543B6-9BCC-4077-A035-9333C65E6F79Q40646993-935F0C1C-E652-4176-8A00-8C0F46526B87Q41340903-4E04D321-A5CD-4375-9E01-878AF7C97949Q41450925-961906A8-7E13-4D4B-AA1F-3A104E949CC8Q43083716-82373B61-6CE4-4D35-B705-29A6CA5207F0Q43097170-22E2F656-0BFD-4CE1-9C04-E08AA1E73774Q43995176-6473D4E6-F345-4E56-A800-0922B91E3371Q44829656-75F7C49A-51DC-441F-80CA-DD6373322BA1Q45882718-F24C0F84-567F-4902-B033-8F5B29945186Q46146104-23BB4CA9-49CA-46B0-A18B-021B3489E3FCQ46157495-7CCB439D-E30B-47B5-8E38-9DE1D6F017F1Q46174588-0B96D00C-2298-4FA1-861B-2505E0A4435CQ47848134-BBF17BC5-8D00-498F-BEFF-F43891963D45Q47892252-42A5CF2F-CA38-4460-93D1-2DCDC462968FQ48218708-F6A7727E-92F4-494B-BCCA-E7A5728435F0Q50035982-3FF4DFCF-439C-4C9A-9C05-15F6486B020CQ50471175-B1BAA024-8A8A-4BE1-BF82-EEE94DA867D9Q50618567-661AADD5-F7D5-4427-B563-1CEF64AA82C4Q50671523-07907E50-0CE0-4E65-90F0-8EDAE325079AQ50788340-36ADCB1B-E415-4360-B6B0-297A0640875CQ52859139-423F3717-B3C5-463B-8653-412002ED5085Q57204184-462F24EE-EE9E-45E4-83EB-095C0490DF5CQ64983621-6AC68A5D-F77B-4B8B-B2D7-2CBEAC2D0AA1Q73119069-BBE02D53-BDDA-49AD-A78B-3696CA01D8A4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Niels Schaft
@ast
Niels Schaft
@en
Niels Schaft
@es
Niels Schaft
@nl
Niels Schaft
@sl
type
label
Niels Schaft
@ast
Niels Schaft
@en
Niels Schaft
@es
Niels Schaft
@nl
Niels Schaft
@sl
prefLabel
Niels Schaft
@ast
Niels Schaft
@en
Niels Schaft
@es
Niels Schaft
@nl
Niels Schaft
@sl
P106
P21
P31
P496
0000-0001-8236-9298